Exhibit 16.1
March 21, 2023
Securities and Exchange Commission
Office of the Chief Accountant
100 F Street N.E.
Washington, D.C. 20549
Re: Shuttle Pharmaceuticals Holdings, Inc.
File Ref. No. 001-41488
We have read the statements made by Shuttle Pharmaceuticals Holdings, Inc., which we understand will be filed with the Commission, pursuant to Item 4.01 of Form 8-K, as part of Shuttle Pharmaceuticals Holdings, Inc. Form 8-K report dated March 21, 2023. We agree with such statements as they pertain to our Firm in such Form 8- K.
We have no basis to agree or disagree with any other statements of the Company contained in Item 4.01.
Sincerely,
BF Borgers CPA PC